Outlook Therapeutics (XTER:41O) E10: €0.00 (As of Mar. 2026)


What is Outlook Therapeutics E10?

Outlook Therapeutics XTER:41O 11 E10 is €0.00 as of Mar. 2026. GuruFocus rates XTER:41O with a GF Score™ of 11/100. The stock has 6 warning signs investors should review.

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Outlook Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.043. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), Outlook Therapeutics's current stock price is €0.00. Outlook Therapeutics's E10 for the quarter that ended in Mar. 2026 was €0.00. Outlook Therapeutics's Shiller PE Ratio of today is .


Outlook Therapeutics  (XTER:41O) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Outlook Therapeutics E10 Related Terms


Outlook Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Outlook Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Outlook Therapeutics E10 Chart

Outlook Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Outlook Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XTER:41O vs FULC, OBIO, ACIU: E10 Comparison

For the Biotechnology subindustry, Outlook Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Outlook Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Outlook Therapeutics's Shiller PE Ratio falls into.



Outlook Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Outlook Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.043/330.2130*330.2130
=-0.043

Current CPI (Mar. 2026) = 330.2130.

Outlook Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -227.840 241.018 -312.158
201609 -34.214 241.428 -46.796
201612 -124.378 241.432 -170.115
201703 -56.848 243.801 -76.997
201706 -31.328 244.955 -42.232
201709 -40.272 246.819 -53.879
201712 -95.992 246.524 -128.579
201803 -43.145 249.554 -57.090
201806 -35.952 251.989 -47.112
201809 -24.017 252.439 -31.416
201812 -17.580 251.233 -23.107
201903 -17.346 254.202 -22.533
201906 -3.540 256.143 -4.564
201909 -6.511 256.759 -8.374
201912 -11.160 256.974 -14.341
202003 -6.516 258.115 -8.336
202006 -0.533 257.797 -0.683
202009 -1.325 260.280 -1.681
202012 -1.973 260.474 -2.501
202103 -1.512 264.877 -1.885
202106 -1.162 271.696 -1.412
202109 -1.360 274.310 -1.637
202112 -1.416 278.802 -1.677
202203 -1.634 287.504 -1.877
202206 -1.514 296.311 -1.687
202209 -1.212 296.808 -1.348
202212 -1.510 296.797 -1.680
202303 -0.486 301.836 -0.532
202306 -1.486 305.109 -1.608
202309 -0.928 307.789 -0.996
202312 -0.789 306.746 -0.849
202403 -7.369 312.332 -7.791
202406 -0.827 314.175 -0.869
202409 0.685 315.301 0.717
202412 0.688 315.605 0.720
202503 -1.387 319.799 -1.432
202506 -0.477 322.561 -0.488
202509 -0.162 324.800 -0.165
202512 -0.325 324.054 -0.331
202603 -0.043 330.213 -0.043

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.00 mean?
Outlook Therapeutics (XTER:41O) has a E10 of €0.00 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Outlook Therapeutics and its competitors.
Is Outlook Therapeutics' E10 too high?
Outlook Therapeutics' current E10 is €0.00. Overall, Outlook Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' E10 compare to FULC and OBIO?
Outlook Therapeutics' E10 of €0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Outlook Therapeutics and its competitors. Outlook Therapeutics's current E10 is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (XTER:41O) has a current E10 of €0.00. The current E10 is €0.00. Outlook Therapeutics' overall GF Score™ is 11/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Outlook Therapeutics (XTER:41O), the current E10 is €0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Outlook Therapeutics Business Description

Other Exchanges OTLK:USA41O:Germany
Address 111 S. Wood Avenue, Suite 100, Iselin, NJ, USA, 08852
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.